By Hendra Lukman 
Every moment, the bone marrow is a bustling factory, generating millions of fresh blood and immune cells. This continuous renewal is a testament to a delicately orchestrated system, a balanced partnership between hematopoietic stem cells (HSCs), supportive stromal cells, and a complex network of immune signals. However, this vital equilibrium is not immutable. Over time, the relentless march of aging, the persistent simmer of chronic inflammation, or the accumulation of subtle genetic errors, known as somatic mutations, can gradually erode the communication channels within these cellular communities. This breakdown can lead to a decline in the normal replenishment of stem cells and, critically, allow for the unchecked proliferation of mutated HSCs. This insidious process gives rise to clonal hematopoiesis of indeterminate potential, or CHIP, a condition that, while often asymptomatic, is far from benign. CHIP affects a significant portion of the aging population, appearing in approximately 10% to 20% of adults over the age of 60, and its prevalence surges to nearly 30% in those exceeding 80.
The implications of CHIP extend far beyond its silent presence. Individuals diagnosed with this condition face a tenfold increased risk of developing blood cancers. Furthermore, their likelihood of experiencing cardiovascular disease and facing premature mortality is doubled. A related, more severe disorder, myelodysplastic syndrome (MDS), also involves clonal HSCs but manifests as inefficient blood-cell production, leading to a progressive failure of the bone marrow. MDS impacts an estimated 20 out of every 100,000 adults over 70, and a concerning approximately 30% of these cases will inevitably advance to acute myeloid leukemia (AML), an aggressive and frequently fatal form of cancer. Despite the grave consequences of these blood disorders, the precise contribution of the bone marrow’s intricate microenvironment – the ecosystem in which these cells reside and interact – to their development has remained a significant scientific enigma.
Mapping the Hidden Landscape of Bone Marrow Remodeling
To illuminate the mechanisms by which mutated HSC clones gain dominance within the bone marrow, an international consortium of researchers, spearheaded by Judith Zaugg from the European Molecular Biology Laboratory (EMBL) and the University of Basel, and Borhane Guezguez from the University Medical Center Mainz (UMC Mainz), embarked on an ambitious molecular and spatial analysis of human bone marrow. The study leveraged samples meticulously collected from the BoHemE cohort study, a collaborative effort involving Uwe Platzbecker at the National Center for Tumor Diseases (NCT) Dresden.
Employing a sophisticated suite of technologies, including single-cell RNA sequencing, advanced biopsy imaging, proteomics, and in-vitro co-culture models, the research team meticulously constructed a detailed map of the bone marrow microenvironment. This comprehensive mapping encompassed both healthy donors, including those with the precursor condition CHIP, and patients diagnosed with MDS. Their groundbreaking analysis unveiled a surprising and previously unrecognized cellular shift that commences long before any overt clinical symptoms become apparent. The researchers identified a gradual displacement of the normal mesenchymal stromal cells (MSCs), which are crucial for supporting stem-cell function, by a distinct population of inflammatory stromal cells.
"I was surprised to observe such pronounced remodeling of the bone marrow microenvironment already in individuals with CHIP, although the underlying cause-and-effect relationships remain unclear," stated Dr. Zaugg, who serves as a co-senior author, an EMBL Group Leader, and a Professor at the University of Basel. This observation suggests that the bone marrow’s internal environment undergoes significant changes, initiating a cascade of events that may predispose individuals to more serious blood disorders.
The Emergence of Inflammatory Stromal Cells and Their Impact
Unlike their healthy counterparts, these newly identified inflammatory MSCs (iMSCs) exhibit a striking characteristic: they produce substantial quantities of interferon-induced cytokines and chemokines. These signaling molecules act as potent attractants, drawing in and activating interferon-responsive T cells. This influx of activated T cells, in turn, amplifies the existing inflammatory activity, creating a self-perpetuating cycle. This detrimental feed-forward loop establishes a state of chronic inflammation within the bone marrow. Such chronic inflammation is known to disrupt the normal, healthy process of blood formation and can also contribute to detrimental vascular changes within the marrow itself.
A critical question addressed by the study was whether the mutated hematopoietic cells themselves directly initiate this inflammatory response. Using a novel computational method called SpliceUp, developed by co-lead author Maksim Kholmatov, an EMBL alumnus, in collaboration with Pedro Moura and Eva Hellström-Lindberg from the Karolinska Institute, the researchers were able to computationally separate mutated cells from non-mutated cells within single-cell datasets. SpliceUp achieves this by detecting aberrant RNA-splicing patterns, a telltale sign of genetic mutations. Their findings revealed that in MDS, the inflammatory network within the microenvironment becomes the dominant force, effectively supplanting much of the bone marrow’s inherent regenerative structure.
"Another striking observation was that MDS stem cells couldn’t trigger stromal cells to produce CXCL12, an important signal that triggers blood cells to settle in the bone marrow," explained Karin Prummel, a co-lead author and EMBL postdoc. "This failure may help explain why the bone marrow stops working properly." CXCL12 is a key chemokine responsible for anchoring hematopoietic stem cells and progenitor cells within the bone marrow niche. Its diminished production could lead to stem cells detaching and potentially migrating out of the supportive microenvironment, hindering effective blood production.
"It was quite surprising to see the lack of a direct inflammatory effect that we could attribute to the mutant cells," added Maksim Kholmatov, co-lead author and EMBL alumnus. "However, when viewed in the context of changes in the T cell and stromal compartments, it underlines the importance of the bone marrow microenvironment in shaping disease progression." This perspective shifts the focus from solely viewing mutated cells as the culprits to recognizing the critical role of the surrounding cellular milieu in dictating the trajectory of disease.
Inflammation as a Primary Driver of Early Blood Disease
The cumulative evidence from this extensive research strongly indicates that inflammation plays a central and perhaps initiating role in the earliest phases of blood disorders like CHIP and MDS. This understanding elevates the bone marrow microenvironment, often referred to as the bone marrow niche, to a prime target for therapeutic intervention. By shifting the therapeutic focus from targeting mutated cells in isolation to addressing the complex ecosystem that supports these aberrant stem cells, the research opens up new avenues for early treatment and, crucially, prevention.
The implications for future therapeutic strategies are profound. The administration of anti-inflammatory drugs or the development of therapies designed to modulate interferon signaling could potentially help preserve normal bone marrow function in older adults who have been diagnosed with CHIP. Furthermore, combining these microenvironment-targeted therapies with existing treatments could offer a powerful strategy to slow or even prevent the progression from CHIP to more aggressive conditions such as MDS or AML. The specific molecular characteristics identified in iMSCs and interferon-responsive T cells may also serve as valuable early biomarkers, enabling the identification of individuals at elevated risk long before clinical manifestations emerge.
"Our findings reveal that the bone marrow microenvironment actively shapes the earliest stages of malignant evolution," emphasized Dr. Guezguez, Principal Investigator in the Department of Hematology at UMC Mainz and co-senior author. "As advances in molecular profiling allow us to detect pre-leukemic states years before clinical onset, understanding how stromal and immune cells interact provides a foundation for preventive therapies that intercept disease progression before leukemia develops." This forward-looking perspective underscores the potential of this research to fundamentally alter how age-related blood disorders are managed.
Beyond Blood Disorders: The Broader Impact on ‘Inflammaging’
The significance of these findings extends beyond the realm of hematological malignancies. The study contributes substantially to a broader scientific understanding of ‘inflammaging’ – the phenomenon of low-grade, chronic inflammation that is increasingly recognized as a key contributor to a wide array of age-related diseases. Conditions such as cancer, cardiovascular disease, and metabolic disorders are all now understood to be influenced by this persistent inflammatory state. The bone marrow, once primarily viewed as a passive site of blood production, is now emerging as a dynamic player, both affected by and actively contributing to systemic inflammatory aging.
By elucidating how intricate interactions between immune and stromal cells drive these inflammatory changes within the bone marrow, this research provides a compelling model for investigating similar inflammatory remodeling processes in other myeloid malignancies and advanced forms of leukemia. This framework could accelerate the development of targeted therapies across a spectrum of related diseases.
"It will be crucial to study these processes over time; our current findings are based on cross-sectional data," cautioned Dr. Zaugg. This acknowledgement highlights the need for longitudinal studies to fully capture the temporal dynamics of these cellular and molecular changes. "This has important implications for therapies that replace malignant cells but leave the bone marrow niche intact, such as blood stem cell transplantation. We are now investigating to what extent the niche retains a ‘memory’ of disease, which could shape how it responds to new, healthy stem cells." The concept of the niche retaining a "memory" of past inflammatory insults or disease processes is a fascinating area of ongoing research, with potential implications for the long-term success of stem cell transplantation.
The work detailed in this article is presented alongside a complementary study that also investigates the MDS bone marrow microenvironment. This related research, also published in Nature Communications and led by Marc Raaijmakers from Erasmus MC Cancer Institute in Rotterdam, collectively offers a more comprehensive and nuanced view of the inflammatory remodeling that occurs during the early, often silent, phases of bone marrow disease.
The collaborative spirit underpinning this research is evident in the extensive network of institutions involved, including UMC Mainz, University of Basel, University Hospital Dresden, Karolinska Institute Sweden, The Jackson Laboratory USA, and Sorbonne University, France, alongside DKTK partner institutions such as DKFZ and NCT Dresden. Funding for this pivotal research was provided by the DKTK-CHOICE programme, an ERC grant (EpiNicheAML) awarded to Judith Zaugg, the MCSA-funded ITN ENHPATHY, EMBO, the Swiss National Foundation, and the José Carreras Leukämie-Stiftung, underscoring the significant international and institutional commitment to unraveling these complex biological processes.
